首页>投融资
Thetis Pharmaceuticals
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
基本信息
-
公司全称Thetis Pharmaceuticals LLC
-
类型炎症性疾病治疗药物研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15人以下
-
地址54 Danbury Rd.,Suite 285 RIDGEFIELD CONNECTICUT 06877; US; Telephone: +12034312446;
-
联系电话
-
邮箱fsciavolino@thetispharma.com
-
成立时间2011-01-01
投融资
-
2025-01-09未公开897.5万美元The Leona M. and Harry B. Helmsley Charitable Trust
-
2019-10-24捐赠/众筹/授予230万美元National Institutes of Health
-
2018-05-23捐赠/众筹/授予190万美元National Institutes of Health
-
2017-11-16捐赠/众筹/授予230万美元National Institutes of Health
- 加载更多
相关投融资企业
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
未公开
Leyden Labs provides a platform that targets commonalities of viral families to protect humanity from known and future viruses.In January 2022, Leyden Laboratories B.V. closed a $140M Series B financing that raised a total of $200M in 2021.In March 2021, Leyden Labs had closed €40 Million Series A financing led by GV (Google Ventures), with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers
种子轮
RyboDyn是一家生物技术公司，率先开发针对暗基因组的一流免疫疗法。通过利用专有测序方法和先进的生物信息学平台 RyboCypher，RyboDyn™ 正在发现和验证以前未知的蛋白质和疾病特异性靶标。凭借其用于潜在客户发现和优化的可扩展内部平台以及从 Oregon Hea 获得许可的专有 IPlth & Science University，RyboDyn正在推动一种独特的“目标到资产”治疗方法进行开发。公司与领先的临床和学术机构以及生物制药合作伙伴合作，验证和推进其药物管线，专注于为癌症和其他医疗需求未得到满足的疾病提供变革性解决方案。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息